Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of GSK2586184 in chronic plaque psoriasis
2012-002917-20Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solcitinib in psoriasis (4 arms), sponsored by GSK. Primary endpoint: PASI 75 response at Week 12. Started Nov 2012; status: completed.
02
Drugs
solcitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2012-002917-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002917-20.